{
  "docId": "019de073-9947-75c9-ab6d-01a31b39af7e",
  "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f",
  "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides",
  "authorId": "third-harmonic-bio",
  "authorName": "Third Harmonic Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 17,
  "pageCount": 24,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide outlines a randomized, placebo-controlled trial structure with specific allergen challenge points.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/17",
  "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e",
  "deckJsonHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e.json",
  "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.65,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Trial timeline showing weeks, days, allergen challenges, SPT, and AHR measurements.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0310e72-10f3-4230-acb5-6ffd015a8b57",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.25,
        "x": 0.7,
        "y": 0.25
      },
      "kind": "list",
      "text": "Established clinical POC model for asthma. Elevated mast cell gene signature. Dose ranging design. Planned study initiation in 1H:23.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5164f6bf-9990-4e30-8f9e-8fab6383e353",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.65,
        "x": 0.03,
        "y": 0.7
      },
      "kind": "list",
      "text": "Study Design: Parallel, Blinded, PBO controlled, 2-3 THB001 doses + PBO (1:1:1): N=~10-15/arm. Patient Population: mild, stable allergic asthmatic subjects. Primary Endpoint: change from baseline in FEV during LAR.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f863e5be-5901-4360-9147-b150118f69c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.12,
        "x": 0.83,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "1Murphy et al. ACS 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0257cbe-612e-4c3d-a25d-b5f8928841ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Phase 1b Inducible Allergic Asthma POC Trial Concept Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2d863d0-cf59-4200-b7dc-395703ab4f10",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 21,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1637e937-fd9b-4682-939c-d684884ac925",
      "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.",
      "position": 0,
      "objective": "What is the cost of not treating mast cell-mediated diseases effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}